AMAG Pharmaceuticals Appoints Frank Thomas as EVP and CFO
AMAG Pharmaceuticals, a biopharmaceutical company focused on the development and commercialisation of a therapeutic iron compound to treat iron deficiency anaemia, has appointed Frank Thomas as executive vice president (EVP) and chief financial officer (CFO). Thomas will be responsible for the company’s finance, accounting, treasury and corporate communications functions, and will report directly to Brian Pereira, president and chief executive officer (CEO).
During his 19-year career, Thomas has held a variety of senior executive roles in the life sciences industry. From 2008 to 2011, he served as senior vice president (SVP), chief operating officer (COO) and CFO for Molecular Biometrics, a medical diagnostics company focused on reproductive medicine where he established the company’s manufacturing, distribution and business processes in support of product development and commercialisation.
Prior to this, Thomas spent four years at Critical Therapeutics, where he was promoted to president and CEO from the position of SVP and CFO to lead a turnaround effort, refocus the company on new product opportunities and improve operational execution. Thomas also served on the board of directors of Critical Therapeutics until 2008.
Prior to 2004, Thomas served as CFO and vice president of finance and investor relations at Esperion Therapeutics, a development-stage biotechnology company focused on a cardiovascular product portfolio where he contributed to the advancement of Esperion’s product portfolio and supported the company through its eventual US$1.3bn acquisition by Pfizer.
Since 2007, Thomas has been a member of the board of directors of the Massachusetts Biotechnology Council.
Thomas’s prior positions include senior director of finance, corporate controller and audit roles with Mechanical Dynamics, and Arthur Anderson LLP from 1992 to 2000, respectively. Thomas holds a BBA in Business Administration from the University of Michigan, Ann Arbor.news item…